The Janssen Pharmaceutical Companies of Johnson & Johnson announced an additional analysis from the landmark CANVAS Program showing Invokana (canagliflozin) improved renal outcomes in people with type 2 diabetes mellitus (T2DM) with or at high risk for cardiovascular (CV) disease. This benefit was observed in people with both preserved and reduced kidney function, as measured by…